Table 3

ROC analysis of CSF parameters

CSF variablesNumber of patients†Youden index‡Associated criterion§Se (%)Sp (%)AUC (95% CI)Cut-off used *
Se (%)Sp (%)
Pro-DLB versus pro-AD
 t-TauDLB n=57
AD n=132
0.682>443 ng/L73.594.70.91 (0.86 to 0.94)81.884.2
 Ph-Tau0.799>62 ng/L88.691.20.93 (0.89 to 0.97)90.286.0
 Aβ420.471≤626 ng/L68.2790.76 (0.69 to 0.82)76.568.4
 t-Tau _ phospho-Tau _ Aβ42¶0.794>0.60486.493.00.93 (0.89 to 0.97)
 Aβ40DLB n=33
AD n=60
0.591>954683.375.80.80 (0.71 to 0.88)
 Aβ42/Aβ400.783≤0.055678.31000.95 (0.88 to 0.98)
 t-Tau _ phospho-Tau _ Aβ42/Aβ40¶0.873>0.57393.393.90.97 (0.91 to 1.00)
DLB-d versus AD-d
 t-TauDLB n=154
AD n=783
0.616>443 ng/L81.779.90.87 (0.84 to 0.89)86.274.7
 Ph-Tau0.636>64 ng/L87.676.00.87 (0.85 to 0.90)91.170.8
 Aβ420.243≤606 ng/L71.053.30.64 (0.61 to 0.67)84.637.0
 t-Tau _ phospho-Tau _ Aβ42¶0.609>0.76977.183.80.87 (0.85 to 0.89)
 Aβ40DLB n=43
AD n=281
0.389>731685.453.50.72 (0.67 to 0.77)
 Aβ42/Aβ400.400≤0.082186.553.50.72 (0.67 to 0.77)
 t-Tau _ phospho-Tau _ Aβ42/Aβ40¶0.512>0.76586.165.10.83 (0.78 to 0.87)
DLB-(Pro+d) versus AD-(Pro+d)**
 t-TauDLB n=211
DLB/AD n=915
0.644>443 ng/L80.683.90.88 (0.86 to 0.90)85.677.3
 Ph-Tau0.675>63 ng/L88.379.20.89 (0.87 to 0.91)9174.9
 t-Tau _ phospho-Tau¶0.683>0.69688.280.10.90 (0.88 to 0.91)
 Aβ40DLB n=76
DLB/AD n=341
0.367>993260.476.30.71 (0.67 to 0.76)
 Aβ42/Aβ400.498≤0.069274.8750.80 (0.76 to 0.84)
 t-Tau _ phospho-Tau _ Aβ42/Aβ40¶0.609>0.73480.780.30.87 (0.84 to 0.90)
  • *Tau >400 ng/L; Aβ42 <700 ng/L; Ph-Tau >60 ng/L.

  • †Due to missing CSF, some patients could not have an Aβ40 assay.

  • ‡Youden index: sensitivity+specificity – 1.

  • §Cut-off point associated to the Youden index.

  • ¶Consideration of these parameters with a multiple regression.

  • **DLB-(Pro+d)=pro-DLB+DLB-d groups; AD-(Pro+d)=pro-AD+AD-d groups.

  • AD, Alzheimer’s disease; AD-d, AD at demented stage; AUC, area under the ROC curve; CSF, cerebrospinal fluid; DLB, dementia with Lewy bodies; DLB-d, DLB at demented stage; pro-AD, AD at prodromal stage; pro-DLB, DLB at prodromal stage; ROC, receiver-operator curve; Se, sensitivity; Sp, specificity.